# Anti-PSMA Antibody (Rosopatamab Biosimilar)

**Cat. No.** AB39

## Description

| | |
|---|---|
| **Reactivities** | Human/Cynomolgus |
| **Target** | PSMA |
| **Isotype** | Human IgG1-Kappa |
| **Conjugation** | Unconjugated |
| **ExpressSystem** | HEK293 |
| **Applications** | ELISA |
| **MolecularWeight** | 50.9 kDa and 23.4 kDa. |
| **Recommended Dilution Buffer** | PBS (pH 7.4), contains no stabilizers or preservatives. |
| **Purification** | protein A |
| **Sterility** | 0.2 μM filtered |
| **Endotoxin** | Less than 1 EU per μg by the LAL method. |
| **Purity** | > 95% as determined by Bis-Tris PAGE |
| | > 95% as determined by HPLC |

## Formulation and Storage

| | |
|---|---|
| **Formulation** | PBS, 10% glycerol (pH 7.4) |
| **Storage** | Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |

## Background

Prostate-specific membrane antigen (PSMA) is an enzyme that in humans is encoded by the FOLH1 (folate hydrolase 1) gene, also known as Glutamate carboxypeptidase II (GCPII). Human PSMA is highly expressed in the prostate, roughly a hundred times greater than in most other tissues. In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells.

## Assay Data

**Bis-Tris PAGE**




Rosopatamab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

**SEC-HPLC**

# Anti-PSMA Antibody (Rosopatamab Biosimilar)

Cat. No. AB39

## Assay Data




The purity of Rosopatamab Biosimilar is greater than 95% as determined by SEC-HPLC.

### ELISA Data




Immobilized Human PSMA, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Rosopatamab Biosimilar with the EC50 of 4.1ng/ml determined by ELISA.